



ISSN: 2231-3354
Received on: 10-05-2012
Revised on: 17-05-2012
Accepted on: 27-05-2012
DOI: 10.7324/JAPS.2012.2633

Effect of Ketoprofen and Indomethacin on Methotrexate Pharmacokinetics in Mice Plasma and Tumor Tissues

Yasmine M. Elmorsi, Sahar M. El-Haggar, Osama M. Ibrahim, and Mokhtar M. Mabrouk

ABSTRACT

Methotrexate (MTX) has been used in combination with nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of inflammatory diseases and malignancies. Severe adverse effects with this combination may occur, usually resulting from inhibition of renal transporters. Solid Ehrlich Carcinoma was induced by implantation of Ehrlich Ascites Carcinoma (EAC) cells subcutaneously into the thigh of mice and after 30 days, mice were divided into 3 groups, Group I served as control group received MTX (50 mg/kg, i.p.), Group II received Ketoprofen (100 mg/kg, i.p.) then after half an hour received MTX (50 mg/kg, i.p.), Group III received Indomethacin (10 mg/kg, i.p.) then after half an hour received MTX (50 mg/kg, i.p.). Plasma and tissue samples were collected at different times then MTX concentrations were determined by HPLC. The injection of Ketoprofen or Indomethacin before MTX injection caused significant increase in the AUC and C_{pmax} of MTX ($p < 0.05$) and significant decrease in CL/F and Vd/F of MTX ($p < 0.05$) in mice plasma. The study showed that administration of ketoprofen or indomethacin prior to MTX caused significant decrease in MTX elimination and significant increase in MTX extent of absorption which may lead to severe adverse effects if coadministered in human.

Keywords: Methotrexate, Solid Ehrlich Carcinoma, Ketoprofen, Indomethacin, NSAIDs, Renal transporters.

INTRODUCTION

Breast cancer is malignant breast neoplasm which originates from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. Cancers originating from ducts are known as ductal carcinomas; those originating from lobules are known as lobular carcinomas (Sariego, 2010). Despite significant advances in surgery, radiation therapy, and anticancer treatment in the past 30 years, chemotherapy resistance remains a major obstacle to improving a cancer patient's outcome. Because there are presently no proven predictors of a patient's response to chemotherapy, all cancer patients selected for chemotherapy receive the same treatment (Lee and Macgregor, 2004).

Y. M. Elmorsi, S. M. El-Haggar, O. M. Ibrahim
*Department of Clinical Pharmacy,
Faculty of Pharmacy, Tanta
University, Tanta 31527, Egypt.*

M. M. Mabrouk
*Department of Analytical Chemistry,
Faculty of Pharmacy, Tanta
University, Tanta 31527, Egypt.*

For Correspondence
Y.M. Elmorsi
*Department of Analytical Chemistry,
Faculty of Pharmacy, Tanta
University, Tanta 31527, Egypt.
Phone: 00201009280119*

Based on currently available preclinical and clinical data, it can be expected that modulation of MRP members may represent a useful approach in the management of anticancer and antimicrobial drug resistance and possibly of inflammatory diseases and other diseases. Many agents of diverse structure and function that modulate MRP have been identified, including calcium channel blockers (e.g., verapamil), immunosuppressive drugs (e.g., cyclosporine A), antibiotics (e.g., erythromycin), probencid, and NSAIDs (Löscher and Potschka, 2005).

Inhibition of ABC-transporters, by using certain inhibitors, was shown to increase the intracellular retention of several drugs like the anti-HIV drugs, and anticancers (Zhou *et al.*, 2008).

Methotrexate is the prototype folate antagonist cytotoxic drug, employed in the therapy of solid tumors and leukaemias, and recently also as an immunosuppressive agent in organ transplantation, in the treatment of some non-malignant diseases such as psoriasis, ankylosing spondylitis and rheumatoid arthritis (Majumdar & Aggarwal, 2001), and in the therapy of severe asthma (Rubino, 2001). Methotrexate and NSAIDs are often used concomitantly in clinical practice such as rheumatoid arthritis and cancer, the combination is reported to increase methotrexate-related adverse effects. The mechanisms responsible for NSAIDs-induced increase in methotrexate concentrations includes decrease in glomerular filtration of methotrexate by NSAIDs via reduction of renal blood flow with inhibition of prostaglandin synthesis (Brouwers and de Smet, 1994), inhibition of methotrexate tubular secretion (El-Sheikh *et al.*, 2007), and competition for protein-binding sites (Brouwers and de Smet, 1994). In general, main interaction mechanism has been known to be the inhibition of prostaglandin synthesis (Brouwers and de Smet, 1994). However, recently, *in vitro* studies have revealed many renal transporters for methotrexate and NSAIDs (Van Aubel *et al.*, 2000; Takeuchi *et al.*, 2001; Shibayama *et al.*, 2006). Organic anion transporters (OAT1, OAT3, OAT4, OAT-K1) (Masada *et al.*, 1997; Takeuchi *et al.*, 2000; Takeda *et al.*, 2002; Uwai *et al.*, 2004), multidrug-resistance proteins (MRP2, MRP4) (El-Sheikh *et al.*, 2007 and Nozaki *et al.*, 2007b), and reduced folate carrier 1 (RFC-1) (Nozaki *et al.*, 2004) are competitive sites between methotrexate and NSAIDs. Considering that the methotrexate main elimination route is the tubular secretion (Rubin *et al.*, 1967 and Nierenberg, 1983), it is speculated that the competition for renal transporters is important mechanism of the interaction in humans.

This study was carried out to examine the effect of two known MRP inhibitors (ketoprofen & indomethacin) on the distribution of methotrexate in experimentally induced mice tumor and also the effect of co-administration of these inhibitors on the overall pharmacokinetics of the drug.

MATERIALS AND METHODS

This study was carried out on adult female Swiss albino mice with an average body weight of 18 - 20 grams. Ehrlich Ascites Carcinoma (EAC) tumor cells obtained from the Pharmacology and Experimental Oncology Unit of the National

Cancer Institute (NCI), Cairo University, Egypt were used where 2.5×10^6 EAC cells were implanted subcutaneously (S.C) into the right thigh of the lower limb of mice. A palpable solid tumor mass developed within 12 days.

On the 30th day postinoculation, mice were randomly divided into the following three groups, each included 60 mice. Mice in group I were given MTX (50 mg/kg i.p.), mice in group II received Ketoprofen (100 mg/kg, i.p.) then after half an hour received MTX (50 mg/kg, i.p.), and mice in group III received Indomethacin (10 mg/kg, i.p.) then after half an hour received MTX (50 mg/kg, i.p.).

Blood and tumor tissue samples were collected at the following time intervals; 0.25, 0.5, 1, 2, 3, 4, 6, and 24 hours after MTX injection. Plasma was carefully separated and the excised tumors were sliced into cubes representing various areas of the tumor and all samples were kept frozen till analysis.

HPLC assay of MTX in mice plasma and tumor tissues

A high performance liquid chromatographic (HPLC) method described by Najjar, (1996) was used to measure MTX concentrations in plasma and tumor tissue samples. The system used consisted of Waters instrument equipped with a 600 E model pump 600 controller u6k injector with 20 μ l loop, 486 uv/vis detector and photodiode array detector and the MilliniumTM program (version 2.1) for data analysis. Initially, plasma samples were deproteinized with trichloroacetic acid. An aliquote of 40 μ l of the supernatant was the injected onto a reversed-phase 15 cm \times 3.9 mm (i.d) C-18, 4 μ m Nova-pakTM column. The mobile phase was composed of phosphate buffer, methanol and Acetonitrile (84:11:5), which was pumped at a flow-rate of 2.3 ml/min. The effluent was monitored at 313 nm.

Tumor samples were carefully weighed (500mg), cut into small pieces, and 5 ml of 0.9% NaCl was added (1:5, w/v), then tissues were homogenized with a Polytron homogenizer. This produces 10% homogenate which was diluted in 1/15 phosphate buffer (pH 7.4 \pm 0.1) and before the samples were injected into the chromatograph, protein denaturing and precipitation procedures were carried out. By adding 200 μ l of 50:50 (v/v) mixture of methanol and 40% ZnSO₄ to 150 μ l of sample. After one minute of vigorous vortex mixing the fluid was centrifuged at 1500 g for 10 min. The supernatant obtained was injected directly onto the HPLC system with a 200 μ l fixed volume.

Pharmacokinetic Analysis

A two compartment model was utilized to describe the plasma concentration time profile of methotrexate. The values of maximum plasma concentration, CP_{max} ; time of maximum concentration T_{max} ; area under the plasma concentration time curve, AUC; elimination rate constant, K_{10} ; elimination half life, $t_{1/2\beta}$; V_d/F and CL/F were determined for each group of mice using the software WinNonlin standard (Version 2.0.0.0, Pharsight corporation, California, USA).

Statistical Analysis

Comparisons between groups were carried out by one way analysis of variance (ANOVA) followed by LSD post hoc test. The level of significance was set at $P = 0.05$.

RESULTS

Assay Validation

The calibration curves were linear over the concentration range of 2-100 $\mu\text{g/ml}$. The equation that describes the linear relationship between peak area ratio and the concentration in the standard curves of MTX was:

Peak area = $8781.262 (\pm 359.5394)$ concentration - $3376.816 (\pm 11364.39)$

The correlation coefficient was always greater than 0.99 during the course of the validation.

The coefficient of variation for the within-day precision ranged from 2.08 % to 19.81 % and the coefficient of variation for the between-day precision ranged from 0.47 % to 12.7 %. The measured plasma MTX concentration relative to the nominal MTX concentration, which is a measure of the accuracy of the assay, ranged from 99.86 % to 119.83 % for the within-day accuracy and from 98.31% to 116.5% for the between-day accuracy. These results indicate good precision and accuracy of the method.

Methotrexate Pharmacokinetic Parameters in Plasma

The mean plasma concentration time curves of MTX (50 mg/kg i.p.), are shown in Figure (1). The mean plasma MTX concentrations observed after injection of MTX (50 mg/kg, i.p) to eight different mice in the three treatment groups are shown in Table (1). The individual MTX pharmacokinetic parameters estimated after injection of MTX (50 mg/kg i.p.) in the three treatment groups are presented in Tables (2), (3), and (4) respectively. The mean pharmacokinetic parameters for MTX after injection of MTX (50 mg/kg i.p.) in the three treatment groups are presented in Table (5).




Fig. 1: The mean plasma MTX concentrations observed after injection of MTX (50 mg/kg, i.p) to eight different mice in the three treatment groups.

Table. 1: The mean plasma MTX concentrations observed after injection of MTX (50 mg/kg, i.p) to eight different mice in the three treatment groups.

Time (hr)	Mean Methotrexate Concentration ($\mu\text{g/ml}$)		
	Group I (MTX alone) (Control group) (n=8)	Group II (MTX+Ketoprofen) (n=8)	Group III (MTX+Indomethacin) (n=8)
0	0	0	0
0.25	31.54 ± 1.23	121.05 ± 2.29	155.71 ± 5.42
0.5	79.37 ± 1.59	208.11 ± 1.96	222.88 ± 17.40
1	16.01 ± 0.53	31.67 ± 3.00	107.95 ± 9.28
2	7.18 ± 0.09	14.26 ± 0.29	51.41 ± 10.36
3	0.21 ± 0.01	1.58 ± 0.04	8.01 ± 2.21
4	0.15 ± 0.01	0.84 ± 0.04	0.28 ± 0.09
6	0.09 ± 0.01	0.36 ± 0.02	0.11 ± 0.01

Table . 2: The individual MTX pharmacokinetic parameters observed after injection of mice with MTX (50 mg/kg i.p.).

Mouse No.	K10 (hr^{-1})	CL/F (ml/hr)	Vd/F (ml)	AUC ($\mu\text{g}\cdot\text{hr/ml}$)	T_{max} (hr)	C_{pmax} ($\mu\text{g/ml}$)	$\frac{1}{2}\beta$ (hr)
1	2.26	5.3	2.35	188.7	0.41	165.19	3.04
2	2.34	5.37	2.29	186.22	0.4	168.01	2.63
3	2.46	5.55	2.25	180.2	0.39	166.15	0.95
4	2.28	5.76	2.53	173.61	0.38	163.86	2.91
5	2.42	5.55	2.29	180.25	0.39	167.46	2.01
6	2.47	5.72	2.32	174.69	0.39	165.21	1.10
7	2.41	6.18	2.57	161.77	0.38	154.77	0.32
8	2.43	5.72	2.35	174.67	0.41	157.69	0.57
Mean	2.38	5.64	2.37	177.51	0.39	163.55	1.69
\pm S.D.	0.08	0.27	0.12	8.41	0.01	4.77	1.09

Table. 3: The individual MTX pharmacokinetic parameters observed after injection of mice with MTX (50 mg/kg i.p) half an hour after injection of Ketoprofen (100 mg/kg i.p).

Mouse No.	K10 (hr^{-1})	CL/F (ml/hr)	Vd/F (ml)	AUC ($\mu\text{g}\cdot\text{hr/ml}$)	T_{max} (hr)	C_{pmax} ($\mu\text{g/ml}$)	$\frac{1}{2}\beta$ (hr)
1	2.26	5.3	2.35	188.7	0.41	165.19	3.04
2	2.34	5.37	2.29	186.22	0.4	168.01	2.63
3	2.46	5.55	2.25	180.2	0.39	166.15	0.95
4	2.28	5.76	2.53	173.61	0.38	163.86	2.91
5	2.42	5.55	2.29	180.25	0.39	167.46	2.01
6	2.47	5.72	2.32	174.69	0.39	165.21	1.10
7	2.41	6.18	2.57	161.77	0.38	154.77	0.32
8	2.43	5.72	2.35	174.67	0.41	157.69	0.57
Mean	2.38	5.64	2.37	177.51	0.39	163.55	1.69
\pm S.D.	0.08	0.27	0.12	8.41	0.01	4.77	1.09

Table. 4: The individual MTX pharmacokinetic parameters observed after injection of mice with MTX (50 mg/kg i.p) half an hour after injection of Indomethacin (10 mg/kg i.p).

Mouse No.	K10 (hr^{-1})	CL/F (ml/hr)	Vd/F (ml)	AUC ($\mu\text{g}\cdot\text{hr/ml}$)	T_{max} (hr)	C_{pmax} ($\mu\text{g/ml}$)	$\frac{1}{2}\beta$ (hr)
1	1.68	3.69	2.2	270.72	0.47	204.76	2.84
2	2.07	4.09	1.98	244.08	0.43	205.35	0.34
3	1.42	3.6	2.54	277.39	0.42	203.39	5.62
4	1.84	3.81	2.07	262.16	0.47	204.5	0.38
5	1.79	3.92	2.19	254.88	0.41	193.14	2.06
6	1.45	3.78	2.61	264.22	0.44	193.55	5.18
7	1.03	3.56	3.43	280.72	0.43	185.59	0.44
8	1.05	3.67	3.48	272.3	0.45	179.3	0.54
Mean	1.54	3.77	2.57	265.81	0.44	196.2	2.18
\pm S.D.	0.37	0.18	0.59	12.13	0.02	9.95	2.19

Table. 5: The mean MTX pharmacokinetic parameters observed after injection of mice with MTX (50 mg/kg i.p) in the three treatment groups.

Treatment group	K10 (hr ⁻¹)	CL/F (ml/hr)	Vd/F (ml)	AUC (µg.hr/ml)	T _{max} (hr)	C _{pmax} (µg/ml)	½β (hr)
Group I (MTX alone) (Control gp.) (n=8)	2.25± 0.11	16.62± 0.41	7.4± 0.49	60.22± 1.47	0.41± 0.01	54.15± 1.56	1.49 ± 0.6
Group II (MTX + ketoprofen)(n=8)	2.38± 0.08	5.64± 0.27*	2.37± 0.12*	177.51± 8.41*	0.39± 0.01	163.55 ± 4.77*	1.69 ± 1.09
Group III (MTX + Indomethacin)(n=8)	1.54± 0.37	3.77± 0.18*	2.57± 0.59*	265.81± 12.13*	0.44± 0.02	196.2± 9.95*	2.18 ± 2.19

* Significantly different from group I (p< 0.05).

There were no significant differences between T_{max} and β_{1/2} in group II which was injected with MTX (50 mg/kg i.p) half an hour after injection of ketoprofen (100 mg/kg i.p) and group I which was injected with MTX (50 mg/kg i.p) alone. The observed T_{max} was 0.41 ± 0.01 hr versus 0.39 ± 0.01 hr, and β_{1/2} was 1.49 ± 0.6 hr versus 1.69 ± 1.09 hr, for group I and group II, respectively. However, there were significant differences between the AUC, C_{pmax}, CL/F, and Vd/F in the two treatment groups. The observed AUC was 60.22 ± 1.47 µg.hr/ml versus 177.51 ± 8.41 µg.hr/ml, C_{pmax} was 54.15 ± 1.56 µg/ml versus 163.55 ± 4.77 µg/ml, CL/F was 16.62 ± 0.41 ml/hr versus 5.64 ± 0.27 ml/hr, and Vd/F was 7.4 ± 0.49 ml versus 2.37 ± 0.12 ml for group I and group II, respectively. Therefore it can be concluded that ketoprofen decreased the elimination of MTX and increased its extent of absorption represented by the increase in C_{pmax} and AUC .

By comparing group III which was injected with MTX (50 mg/kg i.p) half an hour after injection of indomethacin (10 mg/kg i.p) with group I which was injected with MTX (50 mg/kg i.p) alone, we can determine the effect of indomethacin on MTX pharmacokinetics. There were no significant differences between T_{max} and β_{1/2} in the two treatment groups. The observed T_{max} was 0.41 ± 0.01 hr versus 0.44 ± 0.02 hr, and β_{1/2} was 1.49 ± 0.6 hr versus 2.18 ± 2.19 hr, for group I and group III, respectively. However, there were significant differences between the AUC, C_{pmax}, CL/F, and Vd/F in the two treatment groups. The observed AUC was 60.22 ± 1.47 µg.hr/ml versus 265.81 ± 12.13 µg.hr/ml, C_{pmax} was 54.15 ± 1.56 µg/ml versus 196.2 ± 9.95 µg/ml, CL/F was 16.62 ± 0.41 ml/hr versus 3.77 ± 0.18 ml/hr, and Vd/F was 7.4 ± 0.49 ml versus 2.57 ± 0.59 ml for group I and group III, respectively. Therefore it can be concluded that indomethacin decreased the elimination of MTX and increased its extent of absorption represented by the increase in C_{pmax} and AUC.

By comparing group III which was injected with MTX (50 mg/kg i.p) half an hour after injection of indomethacin (10 mg/kg i.p) with group II which was injected with MTX (50 mg/kg i.p) half an hour after injection of ketoprofen (100 mg/kg i.p), we can determine the comparative effects of indomethacin and ketoprofen on MTX pharmacokinetics. There were no significant differences between T_{max} and β_{1/2} and Vd/F in the two treatment groups. The observed T_{max} was 0.39 ± 0.01 hr versus 0.44 ± 0.02 hr, β_{1/2} was 1.69 ± 1.09 hr versus 2.18 ± 2.19 hr, and Vd/F was 2.37 ± 0.12 ml versus 2.57 ± 0.59 ml for group II and group III, respectively. However, there were significant differences between the AUC, C_{pmax}, CL/F, in the two treatment groups. The observed AUC was 177.51 ± 8.41 µg.hr/ml versus 265.81 ± 12.13 µg.hr/ml,

C_{pmax} was 163.55 ± 4.77 µg/ml versus 196.2 ± 9.95 µg/ml, CL/F was 5.64 ± 0.27 ml/hr versus 3.77 ± 0.18 ml/hr, for group II and group III, respectively. Therefore it can be concluded that indomethacin has a more powerful inhibitory effects on MTX elimination than ketoprofen does represented by the decreased CL/F and increased the extent of MTX absorption more than ketoprofen represented by the increased C_{pmax} and AUC .

Methotrexate Pharmacokinetic Parameters in Tumor Tissues

By the analysis of tumor tissue samples collected at the previously specified time intervals by HPLC, Methotrexate could not be detected by this method in any of the samples in the three treatment groups.

DISCUSSION

The comparison of the pharmacokinetic parameters estimated when ketoprofen was injected half an hour before MTX indicates that some pharmacokinetic parameters like AUC, C_{pmax}, CL/F, and Vd/F were significantly changed. The AUC increased to about 2.9 folds while C_{pmax} increased to about 3 folds when ketoprofen was injected before MTX. On the other hand, there was about 2.9 and 3 folds decrease in CL/F, and Vd/F respectively after injection of ketoprofen. There were no significant difference in T_{max} and β_{1/2} between the two groups. These results indicates that ketoprofen decreased the elimination of MTX and increased its extent of absorption represented by the increase in C_{pmax} and AUC . The comparison of the pharmacokinetic parameters estimated when Indomethacin was injected half an hour before MTX indicates that some pharmacokinetic parameters like AUC, C_{pmax}, CL/F, and Vd/F were significantly changed. The AUC increased to about 2.9 folds while C_{pmax} increased to about 3 folds when indomethacin was injected before MTX. On the other hand, there was about 2.9 and 3 folds decrease in CL/F, and Vd/F respectively after injection of indomethacin. There were no significant difference in T_{max} and β_{1/2} between the two groups. These results indicates that indomethacin decreased the elimination of MTX and increased its extent of absorption represented by the increase in C_{pmax} and AUC.

The results obtained in the current study are in agreement with previous experiments involving enhancement of MTX plasma concentrations after the use of different NSAIDs. Thyss *et al.* (1986) reported that simultaneous administration of ketoprofen and MTX was associated with prolonged and striking enhancement of serum MTX levels.

The increase in MTX plasma concentrations in the present study is attributed to the interaction between MTX and NSAIDs that involves inhibition of transporters in proximal renal tubules, and this is supported by several studies. Reid G al. (2003) reported that Indomethacin and ketoprofen inhibited both MRP4 and MRP1 transport but MRP4 proven to be more sensitive than MRP1.

MTX is primarily excreted into urine in the unchanged form, and renal handling involves tubular secretion and reabsorption in addition to glomerular filtration. Renal tubular secretion of MTX has been thought to be a major site of interaction with other drugs (Takeda *et al.*, 2002). El-Sheikh *et al.*, (2006) studied the effect of various NSAIDs on MTX transport in membrane vesicles isolated from cells overexpressing the proximal tubular apical efflux transporters human multidrug resistance protein (MRP2 and MRP4) and found that a wide variety of NSAIDs like indomethacin and ketoprofen inhibited MRP2 and MRP4 mediated methotrexate transport at concentrations to which the transporters may be exposed under therapeutic conditions.

Maeda *et al.*, (2008) determined pharmacokinetic interaction between methotrexate and NSAIDs in rats and found that serum methotrexate concentrations were increased in proportion to NSAID concentration and suggested that this interaction involves inhibition of the transporters in proximal renal tubules. Nierenberg (1983) reported that methotrexate uptake in rabbit kidney slices was inhibited by various NSAIDs. Statkevich *et al.* (1993) demonstrated that tubular clearance of methotrexate was depressed by the concomitant administration of indomethacin or flurbiprofen in the isolated perfused rat kidney. Uwai *et al.* (2000) showed that uptake of methotrexate in the *Xenopus laevis* oocytes was inhibited by Indomethacin and Ketoprofen. Uwai *et al.*, (2011) represented that the NSAIDs significantly increased the area under the blood concentration-time curve of methotrexate and concluded that NSAIDs increase blood levels of methotrexate by influencing renal excretion of the antifolate. On the other hand, several studies suggested that NSAIDs do not significantly affect the disposition of methotrexate, on the contrary to some of the earlier reports. Iqbal *et al.*, (1998) by their studies on the pharmacokinetics of methotrexate in patients with rheumatoid arthritis concurrently taking the most commonly used non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, diclofenac, naproxen, indomethacin, and ibuprofen showed that the area under the curve, the total systemic clearance, the distribution volume, and the half-life of methotrexate in patients receiving concurrent NSAID therapy did not change significantly.

In the current study, no MTX was detected by the analysis of any of the tumor tissue samples taken at the specified time intervals in any of the three treatment groups by the described HPLC method. West *et al.*, (1980) suggested that methotrexate has a limited ability to penetrate into avascular tumor masses and concluded that the limited ability of methotrexate to penetrate solid tumor masses offers an explanation for the limited effectiveness of methotrexate when used for osteosarcoma. Cowan and Tannock (2001) by their studies of the penetration of radiolabelled methotrexate through multicellular layers (MCL) of murine EMT-6

and human MCF-7 cells grown on semiporous teflon membranes had provided an evidence that tissue penetration of methotrexate is through the extracellular space, that its distribution in solid tissue may be limited. Therefore it can be concluded that concurrent use of NSAIDs like ketoprofen or indomethacin with MTX can cause significant increase in MTX extent of absorption which may lead to severe adverse effects and care must be given in such situations.

REFERENCES

- Brouwers J , de Smet P . Pharmacokinetic- pharmacodynamic drug interactions with nonsteroidal anti-inflammatory drugs. *Clinical Pharmacokinetics*. 1994; 27:462-485.
- Cedron L A, Sayalero ML, Lanao JM . High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. *Chromatogr B Biomed Sci Appl*. 1999; 721(2):271-280.
- Cowan DS , Tannock IF . Factors That Influence the penetration of methotrexate through solid tissue. *Int. J. Cancer*. 2001; 91:120–125.
- El-Sheikh AA, Van den Heuvel JJ, Koenderink JB , et al . Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport . *JPET*. 2007; 320 (1):229-235.
- Guo P, Wang X, Liu L, et al . Determination of methotrexate and its major metabolite 7-hydroxymethotrexate in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry. *J Pharm Biomed Anal*. 2007; 43:1789-1795.
- Iqbal MP, Baiga JA, Ali AA, et al . The Effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis . *Biopharm. Drug Dispos*. 1998; 19: 163–170.
- Lee C , Macgregor P . Using microarrays to predict resistance to chemotherapy in cancer patients. *Pharmacogenomics*. 2004; 5(6):611-625.
- Löscher W , Potschka H . Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. *Progress in Neurobiology*. 2005; 76 (1):22-76.
- Maeda A , Tsuruoka S, Kanai Y, et al . Evaluation of the interaction between nonsteroidal anti-inflammatory drugs and methotrexate using human organic anion transporter 3-transfected cells. *European Journal of Pharmacology*. 2008; 596(1-3):166-172.
- Majumdar S , Aggarwal BB . Methotrexate suppresses NF-kappaB activation through inhibition of IkappaB alpha phosphorylation and degradation. *J. Immunol*. 2001; 167(5):2911-2920.
- Najjar TA . Effect of cefoperazone on the pharmacokinetics of methotrexate in the rabbit. *International Journal of Pharmaceutics*. 1995; 131:67-71.
- Nozaki Y, Kusuhara H, Endou H, et al . Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. *J Pharmacol Exp Ther*. 2004; 309: 226-234.
- Rubino FM . Separation methods for methotrexate, its structural analogues and metabolites. *J Chromatogr B Biomed Sci Appl*. 2001; 764(1-2):217-254.
- Shibayama Y, Ushinohama K, Ikeda R, et al . Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. *Cancer Science*. 2006; 97:1260-1266.
- Stewart CF, Fleming RA, Germain BF, et al . Aspirin alters methotrexate disposition in rheumatoid arthritis patients. *Arthritis Rheum*. 1991; 34:1514–520.
- Takeda M, Khamdang S, Narikawa S, et al . Characterization of methotrexate transport and its drug interactions with human organic anion transporters. *J Pharmacol Exp Ther*. 2002; 302(2): 666–671.
- Tracy TS, Worster T, Bradley JD, et al . Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. *Br J Clin Pharmacol*. 1994; 37(5):453-460.

Trédan O, Galmarini CM, Patel K, et al . Drug Resistance and the Solid Tumor Microenvironment. *J Natl Cancer Inst.* 2007; 99: 1441–1454.

Zhou SF, Wang LL, Di YM, et al . Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. *Current Medicinal Chemistry.* 2008; 15 (20):1981-2039.